Welcome to our dedicated page for Phibro Animal Health news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (Nasdaq: PAHC) announced a regulatory change in Brazil after MAPA published Ordinance No. 1617 on April 27, 2026. The ordinance prohibits importation, manufacture, marketing and use of certain growth-promotion antimicrobials, including virginiamycin and bacitracin, after a 180-day transition.
During the 180-day transition companies may continue current sales and labeling; afterward use will require a veterinary prescription. Phibro expects limited impact on fiscal 2026 and will provide more details on its May 7, 2026 earnings call.
Phibro Animal Health (Nasdaq: PAHC) will present at the Bank of America 2026 Virtual Animal Health Summit on Thursday, February 26, 2026 at 10:45 AM ET. Senior leaders including CFO Glenn David, COO Larry Miller and EVP/CEO designate Daniel Bendheim will address analysts and investors.
The live audio presentation and a replay will be available on the company's Investor Relations website and archived for later access.
Phibro Animal Health (Nasdaq: PAHC) reported strong Q2 results for the quarter ended December 31, 2025, with net sales $373.9M (+21%), net income $27.5M, adjusted EBITDA $68.1M (+41%) and raised fiscal 2026 guidance to $1.45B–$1.50B in net sales and $245M–$255M adjusted EBITDA.
Growth was driven by Animal Health, including MFA portfolio contributions, higher gross margin (35.5%), improved free cash flow ($47.3M LTM) and a 3.1x gross leverage ratio as of Dec 31, 2025.
Phibro Animal Health (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on both Class A and Class B common stock. The dividend was declared on Feb 3, 2026, is payable on Mar 25, 2026, to shareholders of record at close of business on Mar 4, 2026.
Phibro Animal Health (Nasdaq: PAHC) will release second quarter results on Wednesday, February 4, 2026 after market close and will host a conference call and webcast on Thursday, February 5, 2026 at 9:00 AM ET.
Investors can join live via the investor site, dial +1 (888) 330-2022 (U.S./Canada) or +1 (365) 977-0051 (international) using conference ID 3927884. A replay will be available about two hours after the live event on the investor website.
Phibro Animal Health (Nasdaq: PAHC) announced a planned leadership transition effective July 1, 2026. Jack Bendheim will move from CEO and President to Executive Chairman while remaining Board Chairman. Daniel (Dani) Bendheim will become Chief Executive Officer and President. Jack has led the company since 1969, served as President since 1988 and was CEO since March 2014. Dani joined in 1997 and has held roles including VP of Business Development, President of Performance Products, Executive VP Corporate Strategy and most recently Chief Transformation Officer overseeing the Phibro Forward initiative. The Board gave unanimous support and the full executive team will remain in place.
Phibro Animal Health (Nasdaq: PAHC) reported a strong start to fiscal 2026 for the quarter ended September 30, 2025, with net sales of $363.9M (up 40%) and net income $26.5M. Animal Health sales rose 55% to $283.5M driven by MFAs, nutritional specialties and vaccines. Adjusted EBITDA for the quarter was $61.9M and management raised FY2026 adjusted EBITDA guidance to $230M–$240M while maintaining net sales guidance of $1.43B–$1.48B. Balance sheet highlights include $749.1M total debt, 3.3x gross leverage and $85.3M cash and short-term investments.
Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on both Class A and Class B common stock. The dividend is payable on December 17, 2025 to stockholders of record at the close of business on November 26, 2025. The declaration was made by the Board of Directors in Teaneck, NJ.
Phibro Animal Health (NASDAQ:PAHC) announced the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease on October 30, 2025. Restoris, developed with a U.S. dental school and licensed to Phibro, is applied into periodontal pockets, cured with supplied UV light, and uses piezoelectric particles to generate microcurrents that stimulate osteoblasts.
Clinical and laboratory studies showed significant reductions in periodontal pocket depth and generation of alveolar bone around the treated tooth within 30 days. Restoris is available for pre-order from Patterson Veterinary Supply and will ship within the next 30 days.
Phibro Animal Health (Nasdaq: PAHC) expects to announce its first quarter results on Wednesday, November 5, 2025 after market close. Management will host a conference call and webcast on Thursday, November 6, 2025 at 9:00 AM Eastern Time.
Investors can access the live presentation and slides at https://investors.pahc.com or dial +1 (888) 330-2022 (U.S./Canada) or +1 (365) 977-0051 (international) and provide conference ID 3927884. A replay of the webcast will be available approximately two hours after the live event at https://investors.pahc.com.